A Phase 3 interventional study of Apixaban and Placebo in Venous Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 429 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-25.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.
Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 6th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 5th registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:
Rushad Patell · Sites in United States
Ages 18+
Clinical Urology and Epidemiology Working Group · Sites in Finland
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
James Bayley · Sites in United States
Ages 18+
University Hospital, Geneva
Ages 18–120
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 12 · Phase 4 10
First in 2004; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,711 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 445 across the 26 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing apixaban in Venous Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT07713875James BayleyExtended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing apixaban in Venous Thrombosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5 mg
Drug: Apixaban
5.0 mg
Drug: Apixaban
0 mg
Drug: Placebo
Tablets, Oral, twice daily, 12 months
Also known as: BMS-562247
Tablets, Oral, twice daily, 12 months
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
VTE included: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.
Time frame: Day 1 up to 12 Months
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
VTE included: nonfatal DVT or nonfatal PE. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted. Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.
Time frame: Day 1 up to 12 months
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation
VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.
Time frame: Day 1 up to 12 Months
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation
VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Composite endpoint included events that occurred any time from randomization until end of the intended treatment period, regardless of whether the participants were receiving drug treatment. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. If there were missing endpoint data, participants were imputed as having had an efficacy outcome event.
Time frame: Day 1 up to 12 Months
Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation
DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.
Time frame: Day 1 up to 12 Months
Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation
PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
Time frame: Day 1 up to 12 Months
Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation
VTE-related death defined as: PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation).
Time frame: Day 1 up to 12 Months
Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation
CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
Time frame: Day 1 up to 12 Months
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
Time frame: Day 1 up to 12 Months
Number of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation
All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. First event category was the first primary event for each participant and each participant was counted once. CV-related death was presented excluding VTE-related death. In participants with event category, each participant was counted once in each event category but could have been counted in multiple categories. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.
Time frame: Day 1 up to 12 Months
Adjudicated Major Bleeding During the Treatment Period - Treated Population
Major bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ; or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
Time frame: Day 1 up to 12 Months
Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants
Major bleeding and clinically relevant non-major bleeding were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Major bleeding was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
Time frame: Day 1 up to 12 Months
Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants
Non-major clinically relevant bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and defined as: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding (or lasting more than 5 minutes); spontaneous hematuria (macroscopic or lasted more than 24 hours after instrumentation of the urogenital tract); macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis (if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
Time frame: Day 1 up to 12 months
Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants
All bleeding events were reviewed by the central independent adjudication committee blinded to treatment and classified as major bleeding, clinically relevant non-major bleeding, minor bleeding or no bleeding. If event was not major or clinically relevant non-major, it was judged to be minor. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
Time frame: Day 1 up to 12 months
Adjudicated Total Bleeding During the Treatment Period - Treated Participants
All bleeding events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Total bleeding was defined as any major, clinically relevant non-major, or minor bleeding. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
Time frame: Day 1 up to 12 months
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation
VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints.
Time frame: Day 1 up to 12 Months
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation
CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event. Index events of DVT and/or PE, along with myocardial infarction and stroke were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.
Time frame: Day 1 up to 12 Months
Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation
DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
Time frame: Day 1 up to 12 Months
Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation
PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
Time frame: Day 1 up to 12 Months
Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation
VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint.
Time frame: Day 1 up to 12 Months
Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation
CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and these were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
Time frame: Day 1 up to 12 Months
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
Time frame: Day 1 up to 12 Months
First participant, first visit: 16 May 2008; Last participant, last visit: 24 August 2012.
| Milestone | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Started | 840 | 813 | 829 |
| Completed | 726 | 684 | 641 |
| Not completed | 114 | 129 | 188 |
| Withdrew: Death | 1 | 3 | 9 |
| Withdrew: Adverse event | 65 | 58 | 126 |
| Withdrew: Withdrawal by subject | 7 | 12 | 6 |
| Withdrew: Lost to follow-up | 2 | 4 | 8 |
| Withdrew: Poor/non-compliance | 5 | 12 | 3 |
| Withdrew: Pregnancy | 2 | 1 | 1 |
| Withdrew: Not meet/no longer meets criteria | 4 | 6 | 4 |
| Withdrew: Other | 28 | 33 | 31 |
VTE included: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation | 0.0381 (0.0252 to 0.0510) | 0.0418 (0.0281 to 0.0556) | 0.1158 (0.0940 to 0.1376) |
VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation | 0.0321 (0.0202 to 0.0441) | 0.0418 (0.0281 to 0.0556) | 0.1110 (0.0896 to 0.1324) |
VTE included: nonfatal DVT or nonfatal PE. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted. Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation | 0.0226 (0.0126 to 0.0327) | 0.0172 (0.0083 to 0.0262) | 0.0929 (0.0731 to 0.1126) |
VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Composite endpoint included events that occurred any time from randomization until end of the intended treatment period, regardless of whether the participants were receiving drug treatment. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. If there were missing endpoint data, participants were imputed as having had an efficacy outcome event.
| proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation | 0.0321 (0.0202 to 0.0441) | 0.0418 (0.0281 to 0.0556) | 0.1146 (0.0929 to 0.1363) |
DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation | 0.0226 (0.0126 to 0.0327) | 0.0344 (0.0219 to 0.0470) | 0.0869 (0.0677 to 0.1060) |
PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation | 0.0274 (0.0163 to 0.0384) | 0.0308 (0.0189 to 0.0426) | 0.0446 (0.0306 to 0.0587) |
VTE-related death defined as: PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation).
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation | 0.0202 (0.0107 to 0.0298) | 0.0295 (0.0179 to 0.0412) | 0.0314 (0.0195 to 0.0432) |
CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
| Proportion of Participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation | 0.0202 (0.0107 to 0.0298) | 0.0295 (0.0179 to 0.0412) | 0.0350 (0.0225 to 0.0475) |
DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation | 0.0262 (0.0154 to 0.0370) | 0.0308 (0.0189 to 0.0426) | 0.0398 (0.0265 to 0.0531) |
All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. First event category was the first primary event for each participant and each participant was counted once. CV-related death was presented excluding VTE-related death. In participants with event category, each participant was counted once in each event category but could have been counted in multiple categories. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.
| participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| First event: Participants with nonfatal DVT | 6 | 7 | 53 |
| First event: Participants with nonfatal PE | 7 | 4 | 13 |
| First event: All-Cause Death | 6 | 3 | 11 |
| CV-related Death (included in all-cause total) | 0 | 0 | 3 |
| VTE-related Death (included in all-cause total) | 2 | 3 | 7 |
| Participants with event: nonfatal DVT | 6 | 8 | 53 |
| Participants with event: nonfatal PE | 8 | 4 | 15 |
| Participants with event: All cause death | 7 | 4 | 14 |
Major bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ; or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Major Bleeding During the Treatment Period - Treated Population | 0.0024 (0.0000 to 0.0057) | 0.0012 (0.0000 to 0.0036) | 0.0048 (0.0001 to 0.0096) |
Major bleeding and clinically relevant non-major bleeding were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Major bleeding was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
| proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants | 0.0321 (0.0202 to 0.0441) | 0.0432 (0.0292 to 0.0571) | 0.0266 (0.0157 to 0.0376) |
Non-major clinically relevant bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and defined as: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding (or lasting more than 5 minutes); spontaneous hematuria (macroscopic or lasted more than 24 hours after instrumentation of the urogenital tract); macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis (if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants | 0.0298 (0.0183 to 0.0413) | 0.0419 (0.0281 to 0.0557) | 0.0230 (0.0128 to 0.0332) |
All bleeding events were reviewed by the central independent adjudication committee blinded to treatment and classified as major bleeding, clinically relevant non-major bleeding, minor bleeding or no bleeding. If event was not major or clinically relevant non-major, it was judged to be minor. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants | 0.0893 (0.0700 to 0.1086) | 0.1208 (0.0984 to 0.1433) | 0.0702 (0.0528 to 0.0876) |
All bleeding events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Total bleeding was defined as any major, clinically relevant non-major, or minor bleeding. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Total Bleeding During the Treatment Period - Treated Participants | 0.1119 (0.0906 to 0.1332) | 0.1492 (0.1247 to 0.1737) | 0.0896 (0.0701 to 0.1091) |
VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints.
| proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation | 0.0167 (0.0080 to 0.0253) | 0.0172 (0.0083 to 0.0262) | 0.0881 (0.0688 to 0.1073) |
CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event. Index events of DVT and/or PE, along with myocardial infarction and stroke were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.
| proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation | 0.0167 (0.0080 to 0.0253) | 0.0172 (0.0083 to 0.0262) | 0.0917 (0.0720 to 0.1113) |
DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
| proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation | 0.0071 (0.0014 to 0.0128) | 0.0098 (0.0031 to 0.0166) | 0.0639 (0.0473 to 0.0806) |
PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation | 0.0095 (0.0030 to 0.0161) | 0.0049 (0.0001 to 0.0097) | 0.0181 (0.0090 to 0.0272) |
VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation | 0.0024 (0.0000 to 0.0057) | 0.0037 (0.0000 to 0.0079) | 0.0084 (0.0022 to 0.0147) |
CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and these were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation | 0.0024 (0.0000 to 0.0057) | 0.0037 (0.0000 to 0.0079) | 0.0121 (0.0046 to 0.0195) |
DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.
| Proportion of participants | Apixaban 2.5 mg | Apixaban 5 mg | Placebo |
|---|---|---|---|
| Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation | 0.0083 (0.0022 to 0.0145) | 0.0049 (0.0001 to 0.0097) | 0.0169 (0.0081 to 0.0257) |
Collected over Day 1 up to 12 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban 2.5mg | — | 112/840 (13.3%) | 341/840 (40.6%) |
| Apixaban 5mg | — | 107/811 (13.2%) | 305/811 (37.6%) |
| Placebo | — | 158/826 (19.1%) | 318/826 (38.5%) |
| Event | Apixaban 2.5mg | Apixaban 5mg | Placebo |
|---|---|---|---|
| DEEP VEIN THROMBOSISVascular disorders | 3/840 | 9/811 | 40/826 |
| PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders | 5/840 | 3/811 | 20/826 |
| PNEUMONIAInfections and infestations | 5/840 | 3/811 | 1/826 |
| PREGNANCYPregnancy, puerperium and perinatal conditions | 3/840 | 4/811 | 1/826 |
| ATRIAL FIBRILLATIONCardiac disorders | 2/840 | 1/811 | 4/826 |
| ANAEMIABlood and lymphatic system disorders | 0/840 | 3/811 | 2/826 |
| MYOCARDIAL INFARCTIONCardiac disorders | 1/840 | 3/811 | 2/826 |
| RESPIRATORY TRACT INFECTIONInfections and infestations | 0/840 | 3/811 | 1/826 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 3/840 | 3/811 | 2/826 |
| MYOCARDIAL ISCHAEMIACardiac disorders | 0/840 | 1/811 | 3/826 |
| Event | Apixaban 2.5mg | Apixaban 5mg | Placebo |
|---|---|---|---|
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 44/840 | 52/811 | 54/826 |
| BACK PAINMusculoskeletal and connective tissue disorders | 27/840 | 45/811 | 24/826 |
| HEADACHENervous system disorders | 44/840 | 41/811 | 42/826 |
| NASOPHARYNGITISInfections and infestations | 41/840 | 31/811 | 40/826 |
| DIARRHOEAGastrointestinal disorders | 37/840 | 24/811 | 24/826 |
| URINARY TRACT INFECTIONInfections and infestations | 28/840 | 30/811 | 34/826 |
| HYPERTENSIONVascular disorders | 34/840 | 19/811 | 14/826 |
| OEDEMA PERIPHERALGeneral disorders | 28/840 | 25/811 | 33/826 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 32/840 | 21/811 | 22/826 |
| BRONCHITISInfections and infestations | 24/840 | 30/811 | 13/826 |
All randomized participants regardless of whether treatment was actually received were included; intent to treat (ITT) principle.
| Age Continuous(years) | Apixaban 2.5 mg | Apixaban 5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 56.6 ± 15.3 | 56.4 ± 15.6 | 57.1 ± 15.2 | 56.7 ± 15.4 |
| Sex: Female, Male(Participants) | Apixaban 2.5 mg | Apixaban 5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 353 | 344 | 361 | 1058 |
| Male | 487 | 469 | 468 | 1424 |
| Region of Enrollment(participants) | Apixaban 2.5 mg | Apixaban 5 mg | Placebo | Total |
|---|---|---|---|---|
| Portugal | 1 | 1 | 0 | 2 |
| United States | 88 | 75 | 96 | 259 |
| Philippines | 5 | 3 | 3 | 11 |
| Hong Kong | 4 | 3 | 4 | 11 |
| Spain | 27 | 25 | 26 | 78 |
| Ukraine | 87 | 77 | 88 | 252 |
| Chile | 2 | 1 | 2 | 5 |
| Russian Federation | 45 | 49 | 46 | 140 |
| Israel | 34 | 34 | 34 | 102 |
| Italy | 67 | 65 | 61 | 193 |
| India | 24 | 23 | 24 | 71 |
| France | 60 | 55 | 50 | 165 |
| Australia | 30 | 28 | 31 | 89 |
| Denmark | 47 | 58 | 42 | 147 |
| South Africa | 34 | 42 | 30 | 106 |
| Korea, Republic of | 4 | 3 | 2 | 9 |
| Austria | 12 | 8 | 11 | 31 |
| United Kingdom | 33 | 29 | 30 | 92 |
| Czech Republic | 43 | 49 | 48 | 140 |
| Mexico | 22 | 18 | 22 | 62 |
| Canada | 22 | 17 | 15 | 54 |
| Argentina | 7 | 9 | 6 | 22 |
| Poland | 45 | 44 | 48 | 137 |
| Brazil | 19 | 24 | 30 | 73 |
| Singapore | 1 | 2 | 3 | 6 |
| Romania | 6 | 7 | 7 | 20 |
| Norway | 9 | 9 | 10 | 28 |
| Germany | 62 | 55 | 60 | 177 |
| Index Event Classification(participants) | Apixaban 2.5 mg | Apixaban 5 mg | Placebo | Total |
|---|---|---|---|---|
| Proximal DVT | 544 | 527 | 551 | 1622 |
| PE | 296 | 286 | 278 | 860 |
Showing the first 100 of 429 sites across 29 countries. Choose a country and city above to see the rest.
The record gives a start of May 2008, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban